172 related articles for article (PubMed ID: 36495382)
21. Antiphospholipid syndrome (APS) in patients with systemic lupus erythematosus (SLE) implies a more severe disease with more damage accrual and higher mortality.
Riancho-Zarrabeitia L; Martínez-Taboada V; Rúa-Figueroa I; Alonso F; Galindo-Izquierdo M; Ovalles J; Olivé-Marqués A; Fernández-Nebro A; Calvo-Alén J; Menor-Almagro R; Tomero-Muriel E; Uriarte-Isacelaya E; Botenau A; Andres M; Freire-González M; Santos Soler G; Ruiz-Lucea E; Ibáñez-Barceló M; Castellví I; Galisteo C; Quevedo Vila V; Raya E; Narváez-García J; Expósito L; Hernández-Beriaín JA; Horcada L; Aurrecoechea E; Pego-Reigosa JM
Lupus; 2020 Oct; 29(12):1556-1565. PubMed ID: 32807021
[TBL] [Abstract][Full Text] [Related]
22. Chinese SLE Treatment and Research group (CSTAR) registry VII: prevalence and clinical significance of serositis in Chinese patients with systemic lupus erythematosus.
Zhao J; Bai W; Zhu P; Zhang X; Liu S; Wu L; Ma L; Bi L; Zuo X; Sun L; Huang C; Tian X; Li M; Zhao Y; Zeng X;
Lupus; 2016 May; 25(6):652-7. PubMed ID: 26762471
[TBL] [Abstract][Full Text] [Related]
23. Hematological involvement in pediatric systemic lupus erythematosus: A multi-center study.
Akca ÜK; Batu ED; Kısaarslan AP; Poyrazoğlu H; Ayaz NA; Sözeri B; Sağ E; Atalay E; Demir S; Karadağ ŞG; Demir F; Bilginer Y; Gümrük F; Özen S
Lupus; 2021 Oct; 30(12):1983-1990. PubMed ID: 34459313
[No Abstract] [Full Text] [Related]
24. Antiphospholipid antibodies and non-thrombotic manifestations of systemic lupus erythematosus.
İlgen U; Yayla ME; Ateş A; Okatan İE; Yurteri EU; Torgutalp M; Keleşoğlu ABD; Turgay TM; Kınıklı G
Lupus; 2018 Apr; 27(4):665-669. PubMed ID: 29050535
[TBL] [Abstract][Full Text] [Related]
25. Prevalence and risk factors for serositis in patients with systemic lupus erythematosus: A case-control study.
Gimeno-Torres L; Carrión-Barberà I; Durán X; Villegas E; Monfort J; Salman-Monte TC
Lupus; 2021 Nov; 30(13):2095-2101. PubMed ID: 34794346
[TBL] [Abstract][Full Text] [Related]
26. Validation of the adjusted global antiphospholipid syndrome score in systemic lupus erythematosus patients in Argentina.
Garcia L; Velloso MS; Martire MV; Savy F; Arizpe F; Garcia N; Testi A; Pena C; Costi AC; Isnardi C; Capelusnik D; Mazza S; Curi YS; Collado V; Rodriguez MF; Scarafia S; Pisoni C; de la Torre M; Seewald A; Riva ME; Garcia M
Lupus; 2020 Dec; 29(14):1866-1872. PubMed ID: 33028177
[TBL] [Abstract][Full Text] [Related]
27. Exploring the risk factors for ischemic cerebrovascular disease in systemic lupus erythematosus: A single-center case-control study.
Su L; Qi Z; Guan S; Wei L; Zhao Y
Front Immunol; 2022; 13():978910. PubMed ID: 36238309
[TBL] [Abstract][Full Text] [Related]
28. Late-onset systemic lupus erythematosus in Latin Americans: a distinct subgroup?
Catoggio LJ; Soriano ER; Imamura PM; Wojdyla D; Jacobelli S; Massardo L; Chacón Díaz R; Guibert-Toledano M; Alvarellos A; Saurit V; Manni JA; Pascual-Ramos V; Silva de Sauza AW; Bonfa E; Tavares Brenol JC; Ramirez LA; Barile-Fabris LA; De La Torre IG; Alarcón GS; Pons-Estel BA;
Lupus; 2015 Jul; 24(8):788-95. PubMed ID: 25504653
[TBL] [Abstract][Full Text] [Related]
29. Chinese SLE Treatment and Research group (CSTAR) registry: Clinical significance of thrombocytopenia in Chinese patients with systemic lupus erythematosus.
Jiang N; Li M; Zhang M; Xu J; Jiang L; Gong L; Wu F; Gu J; Zhao J; Xiang Y; Wang Z; Zhao Y; Zeng X;
PLoS One; 2019; 14(11):e0225516. PubMed ID: 31747435
[TBL] [Abstract][Full Text] [Related]
30. Disease activity, damage and survival in Mexican patients with acute severe systemic lupus erythematosus.
Zonana-Nacach A; Yañez P; Jiménez-Balderas FJ; Camargo-Coronel A
Lupus; 2007; 16(12):997-1000. PubMed ID: 18042596
[TBL] [Abstract][Full Text] [Related]
31. Systemic lupus erythematosus-associated diffuse alveolar hemorrhage: a single-center, matched case-control study in China.
Sun Y; Zhou C; Zhao J; Wang Q; Xu D; Zhang S; Shen M; Hou Y; Tian X; Li M; Zeng X
Lupus; 2020 Jun; 29(7):795-803. PubMed ID: 32321345
[TBL] [Abstract][Full Text] [Related]
32. Superficial vein thrombosis, thrombin generation and activated protein C resistance as predictors of thromboembolic events in lupus and antiphospholipid patients. A prospective cohort study.
Zuily S; Regnault V; Guillemin F; Kaminsky P; Rat AC; Lecompte T; Wahl D
Thromb Res; 2013 Jul; 132(1):e1-7. PubMed ID: 23676348
[TBL] [Abstract][Full Text] [Related]
33. Systemic lupus erythematosus in Tunisia: demographic and clinical analysis of 100 patients.
Houman MH; Smiti-Khanfir M; Ben Ghorbell I; Miled M
Lupus; 2004; 13(3):204-11. PubMed ID: 15119551
[TBL] [Abstract][Full Text] [Related]
34. Risk factors and clinical profile of thrombotic thrombocytopenic purpura in systemic lupus erythematosus patients. Is this a distinctive clinical entity in the thrombotic microangiopathy spectrum?: a case control study.
Merayo-Chalico J; Demichelis-Gómez R; Rajme-López S; Aparicio-Vera L; Barrera-Vargas A; Alcocer-Varela J; Gómez-Martín D
Thromb Res; 2014 Nov; 134(5):1020-7. PubMed ID: 25257921
[TBL] [Abstract][Full Text] [Related]
35. [Pericarditis in systemic lupus erythematosus: prevalence and clinical and immunologic characteristics].
Smiti M; Salem TB; Larbi T; Sfaxi AB; Ghorbel IB; Lamloum M; Houman MH
Presse Med; 2009 Mar; 38(3):362-5. PubMed ID: 19135845
[TBL] [Abstract][Full Text] [Related]
36. Invasive fungal infections in Argentine patients with systemic lupus erythematosus.
Vinicki JP; Catalan Pellet S; Pappalardo C; Cruzat VC; Spinetto MA; Dubinsky D; Tiraboschi IN; Laborde HA; Nasswetter G
Lupus; 2013 Aug; 22(9):892-8. PubMed ID: 23861029
[TBL] [Abstract][Full Text] [Related]
37. Systemic lupus erythematosus and pregnancy: the challenge of improving antenatal care and outcomes.
Pastore DEA; Costa ML; Surita FG
Lupus; 2019 Oct; 28(12):1417-1426. PubMed ID: 31551036
[TBL] [Abstract][Full Text] [Related]
38. Metabolic syndrome is not only a risk factor for cardiovascular diseases in systemic lupus erythematosus but is also associated with cumulative organ damage: a cross-sectional analysis of 311 patients.
Demir S; Artim-Esen B; Şahinkaya Y; Pehlivan Ö; Alpay-Kanıtez N; Omma A; Erer B; Kamalı S; Gül A; Aral O; Öcal L; İnanç M
Lupus; 2016 Feb; 25(2):177-84. PubMed ID: 26354963
[TBL] [Abstract][Full Text] [Related]
39. Clinical features, damage accrual, and survival in patients with familial systemic lupus erythematosus: data from a multi-ethnic, multinational Latin American lupus cohort.
Quintana R; Pons-Estel GJ; Roberts K; Sacnún M; Serrano R; Nieto R; Conti S; Gervasoni V; Catoggio LJ; Soriano ER; Scolnik M; García MA; Alvarellos A; Saurit V; Berbotto GA; Sato EI; Costallat LTL; Neto EFB; Bonfa E; Xavier RM; de Oliveira E Silva Montandon AC; Molina-Restrepo JF; Iglesias-Gamarra A; Guibert-Toledano M; Reyes-Llerena GA; Massardo L; Neira OJ; Cardiel MH; Barile-Fabris LA; Amigo MC; Silveira LH; Torre IG; Acevedo-Vásquez EM; Ugarte-Gil MF; Alfaro-Lozano JL; Segami MI; Chacón-Díaz R; Esteva-Spinetti MH; Gomez-Puerta JA; Alarcón GS; Pons-Estel BA
Lupus; 2020 Aug; 29(9):1140-1145. PubMed ID: 32605527
[TBL] [Abstract][Full Text] [Related]
40. Long-Term Opioid Therapy Among Patients With Systemic Lupus Erythematosus in the Community: A Lupus Midwest Network (LUMEN) Study.
Figueroa-Parra G; Jeffery MM; Dabit JY; Chevet B; Valenzuela-Almada MO; Hocaoglu M; Osei-Onomah SA; Kurani S; Vallejo S; Achenbach SJ; Hooten WM; Barbour KE; Crowson CS; Duarte-García A
J Rheumatol; 2023 Apr; 50(4):504-511. PubMed ID: 36379579
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
